Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER 7: Oral Semaglutide Flexible Dosing vs Sitagliptin in T2DM
NCT02849080Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2016
- Primary completion
- Feb 2018
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Sep 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02849080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02849080.